Global Ticagrelor Market Analysis By Dosage, Application (Acute Coronary Syndrome and Heart Surgeries (Stent Placement, Angioplasty and Coronary Artery Bypass Graft)), Route of Administration (Oral and Nasogastric Tube), End User, Key Players, Insights and Segmentation, Forecast To 2027
Ticagrelor is an antiplatelet drug which is a member of a section of pharmaceuticals which tackle the problem of platelet aggression. Ticagrelor is used to intercept undesirable blood clots which can occur in certain blood vessel. The global Ticagrelor Market size is anticipated to grow at a CAGR of 9% over the forecast period 2017-2027.
Ticagrelor market is expected to grow significantly owing to rising development in the product by the companies, rising occurrence of heart problems, increasing investment in R&D facilities by key players. Moreover, there is a huge opportunity in developing countries that is grabbed by various market players for expanding their presence in the region.
Request Free Sample Report at: https://www.marketresearchfuture.com/sample_request/820
Ticagrelor Market Segmentation:
The global ticagrelor market has been segmented on the basis of
- end-users
- region
By mode of end-users, the global ticagrelor market has been segmented into
- Hospitals
- Clinics
- Medical institutions
Among these, the hospital segment is considered to experience a significant growth rate during the assessment period owing to the well-developed infrastructure and latest devices offered by the hospitals. Moreover, rising incidences of heart attacks are propelling the segment growth.
Global Ticagrelor Market Competitive Analysis
- AstraZeneca
- Eli Lilly
- Boehringer
- Ingelheim, Pfizer
- Amgen
- Merck
- Roche
- GSK
- Alexion
- Boehringer
- Ingelheim Pfizer
- Amgen
are some of the Leading players at the forefront of competition in the Global Ticagrelor Market and are profiled in MRFR Analysis.
There has been increasing development in the product and commercialization of the product. AstraZeneca’s a Swedish multinational pharma and biotech involved in the production since the beginning. Brilinta the company’s product in 2016 generated a sales of about $ 839 million. The product perceived 45% year on year (YoY) revenue growth in the United States and about 15% year on year increase in sales in the European market. The increase in the product revenue is majorly due to changes in the brand name of the competitor product as well as growing use of Brilinta by patients discharged from hospitals in European region. More over the development in Brilinta with the launch of 60-mg version of Brilinta, which in 2016 accounted for 10% of the total prescriptions of the drug in the United States. This development and improving market access for the product is expected to increase the growth of the revenue in 2017 as well. It is expected that the product Brilinta by AstraZeneca to exceed the $ 1.0 billion sales in 2017 and turn out to be a blockbuster therapy.
AstraZeneca furthermore concentrating on commercialization of the product in order to increase product availability across the globe. AstraZeneca announced the collaboration of Sun Pharmaceutical Industries Ltd., according to the agreement the company Sun Phrma agreed to distribute AstraZeneca’s new brand of ticagrelor “Axcer” in India. Sun Pharma is and India’s top pharmaceutical company and the world’s 5th largest specialty generic pharmaceutical company. This collaboration will authorize AstraZeneca to enhance usage of this molecule through wide reach to doctors and thereby helping a greater number of ACS patients.
Global Ticagrelor Market Regional Analysis
The global market is segmented into the various regions including
- Americas
- Europe
- Asia Pacific
- Middle East & Africa
The Americas accounts for the largest market share of about more than ~40% of the market share due to extensive use product by the patients discharged from hospitals in the regions, major manufacturers developing the product in the region.
The Middle East & Africa holds the least share in the ticagrelor market due to lack of awareness, less market access scenarios activities, and poor medical facilities.
Europe is the second largest market of Ticagrelor followed by Asia Pacific. However, Asia Pacific market is expected to grow at the fastest growth rate due to awareness of ticagrelor, Asia Pacific accounting for more than 60% of the global population and increasing cardiovascular patients. Particularly, India and China are anticipated to be a growing and the fastest growing market. Many major players seeking opportunity and expand their presence in this region influencing the growth of the market.
Market Dynamics
Drivers
- Rising Cardiovascular Disorders
- Increasing Geriatric Population
Restraints
- High Bleeding Complications
Opportunities
- Exploring New Applications
Table of Content
- Report Prologue
- Introduction
- Research Methodology
- Market Factor Analysis
- The Global Ticagrelor Market, by Dosage
- The Global Ticagrelor Market, by Route of Administration
- The Global Ticagrelor Market, by Application
- The Global Ticagrelor Market, by End User
- The Global Ticagrelor Market, by Region
- Company Landscape
- Company Profiles
- Appendix
- List of Tables
Browse Full Report @ https://www.marketresearchfuture.com/reports/ticagrelor-market-820
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +16468459312
